Ellis Investment Partners’s Coherus Oncology CHRS Stock Holding History

Ellis Investment Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-700	Closed	-$6K	–	290
2022 Q3	$6K	Hold	700	–	–	﹤0.01%	639
2022 Q2	$5K	Hold	700	–	–	﹤0.01%	669
2022 Q1	$9K	Hold	700	–	–	﹤0.01%	628
2021 Q4	$11K	Hold	700	–	–	﹤0.01%	607
2021 Q3	$11K	Hold	700	–	–	﹤0.01%	590
2021 Q2	$9K	Hold	700	–	–	﹤0.01%	619
2021 Q1	$10K	Hold	700	–	–	﹤0.01%	575
2020 Q4	$12K	Hold	700	–	–	﹤0.01%	538
2020 Q3	$12K	Sell	700 -300	-30%	-$5.58K	﹤0.01%	536
2020 Q2	$18K	Hold	1,000	–	–	0.01%	466
2020 Q1	$15K	Hold	1,000	–	–	0.01%	430
2019 Q4	$18K	Hold	1,000	–	–	0.01%	445
2019 Q3	$19K	Hold	1,000	–	–	0.01%	449
2019 Q2	$22K	Buy	+1,000	New	+$17.4K	0.01%	425

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Ellis Investment Partners's CHRS Position: Q4 2022 in Review

Ellis Investment Partners sold out of Coherus Oncology (CHRS) in Q4 2022, closing a stake of 700 shares — an estimated $6K sold.

Ellis Investment Partners first reported a position in CHRS in Q2 2019 and held it in 14 quarters. The position peaked at $22K in Q2 2019. 161 funds tracked by Wall St. Rank hold CHRS as of Q4 2022.

Ellis Investment Partners reported no remaining Coherus Oncology position as of Q4 2022 after selling out during the quarter.
Ellis Investment Partners sold 700 Coherus Oncology shares in Q4 2022, an estimated $6K.
Ellis Investment Partners first reported a position in Coherus Oncology in Q2 2019 and held it in 14 quarters.
Ellis Investment Partners's Coherus Oncology position peaked at $22K in Q2 2019.
161 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2022.

Based on Ellis Investment Partners's 13F filing for Q4 2022, filed 31 Jan 2023.